Clinical study of tirofiban compared to low molecular weight heparin in the antithrombotic treatment of progressive pontine infarction
CONCLUSIONS: Tirofiban may be more effective and safer than LMWH in controlling the progression of acute pontine infarction, but further and large-sample studies are still needed to confirm this finding.PMID:38567581 | DOI:10.26355/eurrev_202403_35722 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 3, 2024 Category: Drugs & Pharmacology Authors: Q Zhou L-E Xu L-L Lin X-R Huang W-Z Chi J Lin P Lin Source Type: research
One-Month Dual Antiplatelet Therapy Followed by P2Y < sub > 12 < /sub > Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation - The REIWA Region-Wide Registry
CONCLUSIONS: The REIWA region-wide registry suggests that 1-month DAPT followed by P2Y12inhibitor monotherapy is safe and feasible for Japanese patients with BP-DES.PMID:38569870 | DOI:10.1253/circj.CJ-24-0091 (Source: Circulation Journal)
Source: Circulation Journal - April 3, 2024 Category: Cardiology Authors: Masaru Ishida Ryutaro Shimada Fumiaki Takahashi Masanobu Niiyama Takenori Ishisone Yuki Matsumoto Yuya Taguchi Takuya Osaki Osamu Nishiyama Hiroshi Endo Ryohei Sakamoto Kentaro Tanaka Yorihiko Koeda Takumi Kimura Iwao Goto Ryo Ninomiya Wataru Sasaki Tomon Source Type: research
Clinical study of tirofiban compared to low molecular weight heparin in the antithrombotic treatment of progressive pontine infarction
CONCLUSIONS: Tirofiban may be more effective and safer than LMWH in controlling the progression of acute pontine infarction, but further and large-sample studies are still needed to confirm this finding.PMID:38567581 | DOI:10.26355/eurrev_202403_35722 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 3, 2024 Category: Drugs & Pharmacology Authors: Q Zhou L-E Xu L-L Lin X-R Huang W-Z Chi J Lin P Lin Source Type: research
One-Month Dual Antiplatelet Therapy Followed by P2Y < sub > 12 < /sub > Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation - The REIWA Region-Wide Registry
CONCLUSIONS: The REIWA region-wide registry suggests that 1-month DAPT followed by P2Y12inhibitor monotherapy is safe and feasible for Japanese patients with BP-DES.PMID:38569870 | DOI:10.1253/circj.CJ-24-0091 (Source: Circulation Journal)
Source: Circulation Journal - April 3, 2024 Category: Cardiology Authors: Masaru Ishida Ryutaro Shimada Fumiaki Takahashi Masanobu Niiyama Takenori Ishisone Yuki Matsumoto Yuya Taguchi Takuya Osaki Osamu Nishiyama Hiroshi Endo Ryohei Sakamoto Kentaro Tanaka Yorihiko Koeda Takumi Kimura Iwao Goto Ryo Ninomiya Wataru Sasaki Tomon Source Type: research
Clinical study of tirofiban compared to low molecular weight heparin in the antithrombotic treatment of progressive pontine infarction
CONCLUSIONS: Tirofiban may be more effective and safer than LMWH in controlling the progression of acute pontine infarction, but further and large-sample studies are still needed to confirm this finding.PMID:38567581 | DOI:10.26355/eurrev_202403_35722 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 3, 2024 Category: Drugs & Pharmacology Authors: Q Zhou L-E Xu L-L Lin X-R Huang W-Z Chi J Lin P Lin Source Type: research
One-Month Dual Antiplatelet Therapy Followed by P2Y < sub > 12 < /sub > Inhibitor Monotherapy After Biodegradable Polymer Drug-Eluting Stent Implantation - The REIWA Region-Wide Registry
CONCLUSIONS: The REIWA region-wide registry suggests that 1-month DAPT followed by P2Y12inhibitor monotherapy is safe and feasible for Japanese patients with BP-DES.PMID:38569870 | DOI:10.1253/circj.CJ-24-0091 (Source: Circulation Journal)
Source: Circulation Journal - April 3, 2024 Category: Cardiology Authors: Masaru Ishida Ryutaro Shimada Fumiaki Takahashi Masanobu Niiyama Takenori Ishisone Yuki Matsumoto Yuya Taguchi Takuya Osaki Osamu Nishiyama Hiroshi Endo Ryohei Sakamoto Kentaro Tanaka Yorihiko Koeda Takumi Kimura Iwao Goto Ryo Ninomiya Wataru Sasaki Tomon Source Type: research
Clinical study of tirofiban compared to low molecular weight heparin in the antithrombotic treatment of progressive pontine infarction
CONCLUSIONS: Tirofiban may be more effective and safer than LMWH in controlling the progression of acute pontine infarction, but further and large-sample studies are still needed to confirm this finding.PMID:38567581 | DOI:10.26355/eurrev_202403_35722 (Source: European Review for Medical and Pharmacological Sciences)
Source: European Review for Medical and Pharmacological Sciences - April 3, 2024 Category: Drugs & Pharmacology Authors: Q Zhou L-E Xu L-L Lin X-R Huang W-Z Chi J Lin P Lin Source Type: research
Risk and Benefit of Secondary Prevention with Aspirin Versus P2Y12 Inhibitor in CAD Patients
Clinical question: In patients with coronary artery disease (CAD), what is the difference in risk and benefit between secondary prevention with aspirin (ASA) versus a P2Y12 inhibitor?
Background: Lifelong ASA is the mainstay of care for patients with CAD who require secondary prevention. This is predicated on studies from several decades ago. Subsequent studies examining P2Y12 monotherapy versus ASA have had inconsistent results.
Study design: Systematic review and meta-analysis
Setting: Seven randomized clinical trials from 1996 to 2021 were found to meet the criteria for analysis.
Synopsis: 24,325 patients were included ...
Source: The Hospitalist - April 1, 2024 Category: Hospital Management Authors: Ronda Whitaker Tags: Cardiology In the Literature Source Type: research
Huanglian Jiedu decoction inhibits vascular smooth muscle cell-derived foam cell formation by activating autophagy via suppressing P2RY12
CONCLUSIONS: HLJDD inhibited AS in vivo and foam cell formation in vitro by restoring P2RY12/PI3K/AKT signaling pathway-suppressed autophagy. This study is the first to reveal an interaction between P2RY12 and PI3K3CB.PMID:38561055 | DOI:10.1016/j.jep.2024.118125 (Source: Atherosclerosis)
Source: Atherosclerosis - April 1, 2024 Category: Cardiology Authors: Jinhai Lin Mingyang Gu Xiaolong Wang Yuanyuan Chen Nhi Van Chau Junlong Li Qingmin Chu Lijin Qing Wei Wu Source Type: research
Safety of Clopidogrel vs. Ticagrelor in Dual Antiplatelet Therapy Regimens for High-Bleeding Risk Acute Coronary Syndrome Patients: A Comprehensive Meta-analysis of Adverse Outcomes
ConclusionBoth drugs are generally safe for treating ACS patients with HBR at baseline, although a higher risk of MI was observed with the use of clopidogrel. Nevertheless, drug choice should factor in regional variations, patient-specific characteristics, cost, accessibility, and potential drug interactions. (Source: High Blood Pressure and Cardiovascular Prevention)
Source: High Blood Pressure and Cardiovascular Prevention - April 1, 2024 Category: Cardiology Source Type: research
Low-dose prasugrel versus standard-dose ticagrelor in east Asian patients with acute coronary syndrome
This study included ACS patients who underwent percutaneous coronary intervention and, at discharge between January 1, 2018 and December 31, 2020, were prescribed with low-dose prasugrel plus aspirin or standard-dose ticagrelor plus aspirin. Stabilized inve rse probability of treatment weighting was used to balance the covariates across these two groups. The primary effectiveness outcome was a composite of acute myocardial infarction, ischemic stroke, and cardiovascular death; the secondary effectiveness outcome was each of the individual components of the primary outcome, transient ischemic attack, and repeat revasculariz...
Source: Journal of Thrombosis and Thrombolysis - March 31, 2024 Category: Hematology Source Type: research
